共 136 条
[1]
Locatelli F(2004)Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure Nephrol Dial Transplant 19 ii1-47
[2]
Aljama P(2006)KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease Am J Kidney Dis 47 S11-145
[3]
Bárány P(2006)Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia Lancet 368 947-53
[4]
Macdougall IC(2006)Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease Clin J Am Soc Nephrol 1 1211-5
[5]
Eckardt K-U(2008)Comparative erythropoietin receptor binding kinetics of C.E.R.A and epoetin-β determined by surface plasmon resonance and competition binding assay. Pharmacology 81 63-9
[6]
Macdougall IC(2006)Efficacy and immuno-genicity of novel erythropoietic agents and conventional rhE-PO in rats with renal insufficiency Kidney Int 69 60-7
[7]
Robson R(2007)Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycolepoetin beta are unaffected by the site of subcutaneous administration J Clin Pharmacol 47 1390-7
[8]
Opatrna S(2007)C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disesase Expert Opin Investig Drugs 16 1649-61
[9]
Jarsch M(2005)CERA (continuous erythropoiesis receptor activator): dose-response, pharmacokinetics, and tolerability in phase I multiple ascending dose studies Support Oncol 3 10-1
[10]
Brandt M(2006)Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study Int J Clin Pract 60 1687-96